The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
The purpose of this study is to compare the efficacy and safety of arlo-cel (BMS-986393) versus standard regimens in adult participants with Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma.
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
-
Local Institution - 0071, Birmingham, Alabama, United States, 35205
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States, 90404
Local Institution - 0130, Miami, Florida, United States, 33136
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States, 30322
Local Institution - 0196, Boston, Massachusetts, United States, 02118
Local Institution - 0067, Charlotte, North Carolina, United States, 28204
Local Institution - 0216, Winston-Salem, North Carolina, United States, 27157
Local Institution - 0193, Cleveland, Ohio, United States, 44195
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States, 19111
Local Institution - 0044, Salt Lake City, Utah, United States, 84112
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2032-06-22